Urothelial Cancer | Specialty

Pembrolizumab Plus Gemcitabine/Hypofractionated Radiotherapy Demonstrates Promising Efficacy in Muscle-Invasive Bladder Cancer

June 7th 2021

Pembrolizumab in combination with gemcitabine and concurrent hypofractionated radiotherapy appears to be a promising and efficacious, bladder-sparing regimen for patients with muscle-invasive bladder cancer.

Dr. Talwar on the Utility of Immunotherapy in Metastatic Urothelial Carcinoma

May 24th 2021

Vineet Talwar, DM, FRCP, DNB, FICP, FIMSA, MNAMS, discusses the utility of immunotherapy in metastatic urothelial carcinoma.

Grivas and Wright Weigh In on the Benefits of Multidisciplinary Care in Bladder Cancer

May 17th 2021

Drs Grivas and Wright discussed the goals of the Seattle Cancer Care Alliance Bladder Cancer Multidisciplinary Clinic, data that support the use of a multidisciplinary approach in bladder cancer, and the lingering effects of the COVID-19 pandemic on collaboration across health care specialties.

Dr. Sonpavde on Anticipated Data in Bladder Cancer

May 12th 2021

Guru P. Sonpavde, MD, discusses anticipated data in bladder cancer.

FDA Grants Priority Review to Adjuvant Nivolumab for Muscle-Invasive Urothelial Carcinoma

April 30th 2021

The FDA has granted a priority review designation to a supplemental biologics license application for nivolumab for use as an adjuvant treatment in patients with surgically resected, high-risk, muscle-invasive urothelial carcinoma.

Key Considerations for Choosing Between Erdafitinib and Enfortumab Vedotin in Urothelial Carcinoma

April 29th 2021

Michael E. Devitt, MD, further underscored the importance of early genomic testing in patients with urothelial carcinoma, shared advice on factors to consider when choosing among second-line and later options, and highlighted enfortumab vedotin combination regimens that are under exploration.

FDA Grants Priority Review to 2 sBLAs for Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Cancer

April 19th 2021

The FDA has granted priority review to 2 supplemental biologics license applications for enfortumab vedotin-ejfv for the treatment of select patients with locally advanced or metastatic urothelial cancer.

Research Reflections: Sonpavde on Urothelial Cancer Updates From the 2021 GU Cancers Symposium

April 15th 2021

Dr. Sonpavde discusses key data presented during the 2021 Genitourinary Cancers Symposium in urothelial carcinoma and anticipated research directions with immunotherapy, chemotherapy, and antibody-drug conjugates.

Dr. Tagawa on the FDA Approval of Sacituzumab Govitecan in Advanced Urothelial Carcinoma

April 14th 2021

Scott T. Tagawa, MD, MS, FACP, discusses the FDA approval of sacituzumab govitecan-hziy in advanced urothelial carcinoma.

FDA Approves Sacituzumab Govitecan for Advanced Urothelial Cancer

April 13th 2021

The FDA has granted an accelerated approval to sacituzumab govitecan for the treatment of patients with locally advanced or metastatic urothelial cancer who previously received a platinum-containing chemotherapy and either a PD-1 or PD-L1 inhibitor.

Research Runs Rampant With Immunotherapy in Urothelial Carcinoma

April 9th 2021

Sequential chemotherapy and immunotherapy became the preferred standard of care in patients with advanced urothelial carcinoma, based on findings from the phase 3 JAVELIN Bladder 100 trial.

Avelumab Maintenance Makes a Mark on the Bladder Cancer Treatment Paradigm

April 9th 2021

Robert Dreicer, MD, discusses the optimal use of checkpoint inhibitors in urothelial carcinoma.

Enfortumab Vedotin Shows Superior Efficacy Over Chemo in Previously Treated Urothelial Carcinoma

February 13th 2021

February 13, 2021 - Enfortumab vedotin was found to have superior efficacy over chemotherapy when used in patients with advanced urothelial carcinoma who had received prior platinum-based chemotherapy and PD-1/L1 inhibition.

Avelumab as Frontline Maintenance Maintains OS Benefit in Japanese Subgroup of Advanced Urothelial Cancer

February 11th 2021

February 11, 2021 - Avelumab as frontline maintenance therapy plus best supportive care showed a favorable benefit-risk balance in Japanese patients with advanced urothelial cancer that did not progress on first-line chemotherapy.

test-figure-caption

January 29th 2021

summary

Rapid Readouts: TROPHY-U-01 Cohort 1 Final Results

October 14th 2020

Dr. Grivas on the Subgroup Analyses of the JAVELIN Bladder 100 Trial in Advanced Urothelial Cancer

September 24th 2020

Petros Grivas, MD, PhD, discusses findings from the subgroup analyses of JAVELIN Bladder 100 in advanced urothelial cancer.

Long-Term Follow-Up Shows Encouraging OS With Enfortumab Vedotin in Urothelial Carcinoma

September 20th 2020

Long-term follow-up of patients with locally advanced or metastatic urothelial carcinoma treated with enfortumab vedotin monotherapy showed encouraging results, with half of patients still alive at 12 months and approximately one-third alive at 18 months.

Immune-Related Biomarkers Linked With OS Benefits of Frontline Maintenance Avelumab in Advanced Urothelial Carcinoma

September 20th 2020

Overall survival benefits of frontline maintenance treatment with avelumab in patients with advanced urothelial cancer were found to be positively associated with biomarkers of immune activity and negativity linked with biomarkers of tumor homeostasis and chronic inflammation.

Bright Future in Advanced Urothelial Cancer

August 26th 2020